Skip to main navigation

Investors
News
- News Releases
- News and Mentions
Presentations & Events
- Presentations
- Events
Stock Performance
- Stock Information
- Analyst Coverage
Financials & Filings
- SEC Filings
- Quarterly Results
Corporate Governance
Resources

News Releases

Year

Mar 31 / 23

Belite Bio Reports Full-Year 2022 Operational Highlights and Financial Results

Mar 31 / 23

Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results

Mar 08 / 23

Belite Bio announces submission of Clinical Trial Application for Phase 3 Stargardt Disease study of Tinlarebant (LBS-008) in South Korea

Jan 31 / 23

Belite Bio Submits IND Amendment to Initiate Phase 3 Clinical Trial of Tinlarebant (LBS-008) in Advanced Dry AMD

Jan 11 / 23

Belite Bio Receives Approval to Initiate Tinlarebant (LBS-008) Phase 3 Clinical Trial for Stargardt Disease in the Netherlands

Jan 05 / 23

Belite Bio announces submission of Clinical Trial Application for Netherlands Phase 3 study of Tinlarebant (LBS-008)

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Current page 4

Displaying 28 - 33 of 33

Belite Bio™ Inc
12750 High Bluff Drive Suite 475,
San Diego CA, 92130 USA

Join our mailing list.

Sign up to receive important updates and news from Belite Bio